10-year Follow-up of the Ponto Wide-implant
Launched by UNIVERSITY MEDICAL CENTER NIJMEGEN · Jan 9, 2025
Trial Information
Current as of November 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is a single-center, prospective observational study in Nijmegen, Netherlands, following people who already had a Ponto Wide bone-anchored hearing implant implanted at least 10 years ago. Researchers want to learn whether the implant stays in place for 10 years (implant survival) and to explore secondary questions like how often implants or their connecting parts are lost or removed and why, how stable the implant is, skin problems around the implant, how many hours per day the sound processor is used, and overall quality of life after the implant. About 64 participants are planned, and they will be checked during routine clinic visits over the study period.
Eligible participants are children or adults of any sex who received a Ponto Wide implant (4.5 mm diameter, 4.0 mm length) at least 10 years ago and who previously took part in one of two Oticon Medical studies; they must consent to join. There are no specific extra health exclusions listed. Participating involves a clinic visit between November 2024 and March 2025, where clinicians will examine the skin around the implant, measure stability, and have the person complete two questionnaires about hearing-related quality of life. The study does not involve new drugs or treatments, and individual participant data will not be shared publicly.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Implantation with Ponto Wide implant (diameter 4.5 mm, length 4.0 mm)
- • Ten or more years of post-operative follow-up.
- • Valid informed consent
- Exclusion Criteria:
- • No specific exclusion criteria have been set for the study.
About University Medical Center Nijmegen
University Medical Center Nijmegen (UMC Nijmegen) is a leading academic medical center located in the Netherlands, renowned for its commitment to innovative research, high-quality patient care, and advanced medical education. As a key player in clinical trials, UMC Nijmegen leverages its multidisciplinary expertise and state-of-the-art facilities to conduct pioneering studies that aim to enhance treatment options and improve health outcomes. The center collaborates with various national and international partners to foster translational research, ensuring that scientific advancements are effectively integrated into clinical practice. With a strong focus on ethical standards and patient safety, UMC Nijmegen is dedicated to contributing valuable insights to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, Gelderland, Netherlands
Patients applied
Trial Officials
Emmanuel Myalnus, Prof. dr.
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported